针对SLC4A4:结肠直肠癌药物重定位的新方法
Krunal Pawar1, Pramodkumar P Gupta2, Pooran Singh Solanki3,4
1Amity Institute of Biotechnology, Amity University Rajasthan, SP-1, Kant Kalwar, RIICO Industrial Area, NH-11C, Jaipur 303002, Rajasthan, India.
Current issues in molecular biology
|January 24, 2025
概括
研究人员确定了一种有前途的化合物,DB07991,向SLC4A4转运器治疗结直肠癌 (CRC). 这种计算方法通过调节瘤酸度和免疫反应,为CRC提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 计算生物学 计算生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 结肠直肠癌 (CRC) 提出了重大的治疗和预后挑战.
- 在CRC进展,瘤酸度和免疫反应中SLC4A4转运体的作用需要进一步研究.
研究的目的:
- 探索SLC4A4作为结直肠癌中的潜在生物标志物和治疗标.
- 使用计算方法识别潜在的SLC4A4抑制剂.
主要方法:
- 使用基于接收器的虚拟选和高通量对接.
- 我们生成了一个人类SLC4A4模型 (PDB ID 6CAA).
- 来自DrugBank的候选药物使用DrugRep和CB-DOCK2.2进行了评估.
主要成果:
- 化合物 (5R) -N-[(1r) -3-(4-氧) 丁]-2-decanamide (DB07991) 成为具有良好的结合亲和力和稳定性的顶级配体.
- 分子动力学模拟证实了稳定的蛋白质-配体相互作用和SLC4A4结构完整性.
结论:
- 通过向SLC4A4.4,DB07991显示出作为结直肠癌治疗剂的前景.
- 计算药物重新定位是发现新型CRC治疗的可行策略.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K


